2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

801. Gene Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Transplantation, Gene Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, Immunodeficiency, Myeloid Malignancies, Acute Myeloid Malignancies, Research, AML, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Pediatric, Young Adult, Animal Model
PAPER

6067 Optimizing genome editing for therapeutic fetal hemoglobin induction and erythroid rescue in β-thalassemia

Georgios E Christakopoulos, MD, Shruthi Suryaprakash, MD2, Alfonso G. Fernandez, PhD3, Yu Yao, MD4, Michael W Dudley5, Kalin Mayberry6, Yichao Li, PhD7, Nikitha Nimmagadda8, Erin DeWitt9, Razan R.A Sweileh10, Rachel Levine, PhD11, Jonathan Yen, PhD12, Mitchell Weiss, MD, PhD13
1 St Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St Jude Children's Research Hospital, Memphis, Tennessee, United States
3 St Jude Children's Research Hospital, Memphis, Tennessee, United States
4 St Jude Children's Research Hospital, Memphis, Tennessee, United States
5 St Jude Children's Research Hospital, Memphis, Tennessee, United States
6 St Jude Children's Research Hospital, Memphis, Tennessee, United States
7 St Jude Children's Research Hospital, Memphis, Tennessee, United States
8 St Jude Children's Research Hospital, Memphis, Tennessee, United States
9 St Jude Children's Research Hospital, Memphis, Tennessee, United States
10 University of Pennsylvania, Philadelphia, Pennsylvania, United States
11 St Jude Children's Research Hospital, Memphis, Tennessee, United States
12 St Jude Children's Research Hospital, Memphis, Tennessee, United States
13 St Jude Children's Research Hospital, Memphis, Tennessee, United States

Background: Induction of fetal hemoglobin (HbF, α2γ2) alleviates β-thalassemia by correcting globin subunit imbalance, but whether different HbF-inducing genome-editing strategies provide equivalent biological correction remains unknown. We compared adenine base editing (ABE) installation of the HPFH-associated γ-globin −175 A>G variant with CRISPR-Cas9 disruption of the BCL11A binding site in the γ-globin promoter (BCL11A-BS), which induces HbF similarly to exagamglogene autotemcel, an approved therapy that activates γ-globin via Cas9 disruption of the BCL11A erythroid enhancer.

Methods: CD34+ hematopoietic stem and progenitor cells (HSPCs) from two transfusion-dependent β⁰/β⁰-thalassemia donors were edited with ABE8e-NGG or Cas9 ribonucleoproteins, then analyzed after in vitro erythroid differentiation or transplantation into immunodeficient NBSGW mice. Functional correction was assessed by γ-globin expression, globin protein balance, free α-globin accumulation, erythroid maturation, reticulocyte formation, and apoptosis. scRNA-seq evaluated the erythroid transcriptome during erythroid maturation.

Results: Although Cas9 BCL11A-BS editing achieved higher editing efficiencies than ABE −175 A>G (94.9 ± 0.3% and 95.4 ± 0.6% vs 71.0 ± 0.3% and 80.4 ± 1.3% in donors 1 and 2, respectively), ABE consistently produced greater correction: γ-globin mRNA increased ~14-fold after ABE vs 8-fold after Cas9 BCL11A-BS editing in donor 1 and ~12-fold vs 8-fold in donor 2 (both P<0.05). −175 A>G editing restored globin stoichiometry and eliminated free α-globin (0.0% in both donors), compared with residual free α-globin after BCL11A-BS editing (6.0 ± 1.0% and 5.5 ± 0.5% vs untreated 34.7 ± 3.1% and 26.3 ± 2.5% in donors 1 and 2, respectively; both P<0.0001). Restoration of globin stoichiometry yielded functional rescue. In vitro reticulocyte formation increased from 14.9 ± 3.2% to 46.7 ± 0.5% in donor 1 and from 5.7 ± 1.2% to 32.7 ± 1.5% in donor 2 after ABE −175 A>G, exceeding Cas9 BCL11A-BS (33.8 ± 1.2% and 18.0 ± 1.0%, respectively; both P<0.001). Apoptosis decreased from 21.7 ± 2.4% to 14.0 ± 1.3% in donor 1 and from 28.3 ± 2.4% to 19.9 ± 3.7% in donor 2 after ABE −175 A>G (both P<0.05), exceeding correction with Cas9 BCL11A-BS (17.8 ± 3.5% and 28.0 ± 5.5%, respectively; P=ns).

After xenotransplantation, both Cas9 and ABE-edited CD34+ HSPCs exhibited high engraftment (>78% in donor 1 and >82% in donor 2) and editing retention. Editing in engrafted erythroblasts was 72.5 ± 15.5% for Cas9 BCL11A-BS and 48.1 ± 6.8% for ABE −175 A>G. Nevertheless, −175 A>G produced greater in vivo correction, mirroring in vitro findings. Reticulocyte formation rose from 7.9 ± 2.3% to 29.8 ± 5.0% in donor 1 and from 5.5 ± 1.4% to 26.9 ± 2.3% in donor 2, exceeding BCL11A-BS (16.3 ± 2.7% and 13.9 ± 2.6%, respectively; P<0.0001 and P<0.01). Similarly, the β-like/α-globin protein ratio was restored to near-normal levels, and free α-globin was nearly undetectable in ABE −175 A>G-edited erythroblasts, outperforming Cas9 BCL11A-BS.

scRNA-seq analysis of β-thalassemic erythroblasts generated in vivo after xenotransplantation of patient CD34+ cells revealed 3,326 differentially expressed genes (DEGs) compared with normal developmental stage-matched erythroblasts, reflecting dysregulation of proteostasis and metabolic pathways, including oxidative phosphorylation, protein folding, heat shock, proteasome, and autophagy. After genome editing to induce HbF, DEGs decreased to 1,250 with Cas9 BCL11A-BS and 826 with ABE −175 A>G, indicating greater correction of disease-associated transcriptional responses.

Conclusions: Despite lower editing efficiency, ABE-mediated installation of the −175 A>G HPFH variant achieved greater correction of β-thalassemia than Cas9 disruption of the BCL11A γ-globin promoter binding site during in vitro and in vivo erythropoiesis. By restoring near-normal β-like/α-globin stoichiometry, eliminating free α-globin, reducing ineffective erythropoiesis (IE), and normalizing disease-associated erythroid transcriptional programs, ABE −175 A>G represents a promising therapeutic strategy for β-thalassemia. More generally, our findings indicate that genome-editing efficacy in β-thalassemia depends on β-like globin expression achieved by different strategies. Thus, it will be informative to compare globin balance and residual IE in β-thalassemia patients receiving approved or experimental gene therapies to induce HbF or express a β-like globin transgene.

Georgios E Christakopoulos, MD: No relevant conflicts of interest to declare.